AR035494A1 - Derivados de pirazina, composiciones farmaceuticas que los comprenden, y los usos de tales compuestos y composiciones en la elaboracion de medicamento - Google Patents
Derivados de pirazina, composiciones farmaceuticas que los comprenden, y los usos de tales compuestos y composiciones en la elaboracion de medicamentoInfo
- Publication number
- AR035494A1 AR035494A1 ARP010104452A ARP010104452A AR035494A1 AR 035494 A1 AR035494 A1 AR 035494A1 AR P010104452 A ARP010104452 A AR P010104452A AR P010104452 A ARP010104452 A AR P010104452A AR 035494 A1 AR035494 A1 AR 035494A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- substituted
- hydroxyalkyl
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Derivados de pirazina que inhiben la actividad de la tirosín quinasa, y que tienen la fórmula (1) o sales farmacéuticamente aceptables de los mismos, en donde: R1 es seleccionado de entre el grupo consistente en cicloalquilo, heterociclilo, biheterociclilo, arilo, biarilo, heteroarilo y biheteroarilo opcionalmente sustituidos con 1 a 5 sustituyentes entre sí seleccionados de entre el grupo consistente en alquilo, alquilo inferior, alquenilo, alquinilo, alcoxi, alcoxi inferior, heterociclilo, heterociclilalquilo, heterociclilalquenilo, heterociclil alquinilo, heterociclilalcoxi, arilo, arilalquilo, arilalquenilo, arilalquinilo, arilalcoxi, heteroarilo, heteroarilalquilo, heteroarilalquenilo, heteroarilalquinilo, heteroaril alcoxi, OH, hidroxialquilo, halógeno, ciano, nitro, amino, alquilamino, alquilaminoalquilo, alquilaminoalquilamino, aminoalquilo, aminoalquilamino, di(alquil)amino, di(alquil)aminoalquilo, di(alquil)aminoalquilamino, (hidroxialquil) amino, di(hidroxialquil)amino, carbamoílo, acilo, acilalquilo, alcoxicarbonilo, alcoxicarbonilalquilo, acilamino, alquilsulfonilo, alquilsulfonilamino, arilsulfonil amino (estando arilo sustituido con de 1 a 3 sustituyentes independientemente entre sí seleccionados de entre el grupo consistente en ciano, halógeno, hidroxi, nitro, alquilo inferior tri (halo) sustituido y alcoxi inferior tri(halo) sustituido, aminosulfonilo, aminosulfonilalquilo, alquilaminosulfonilo, alquilamino sulfonil alquilo, di(alquil)aminosulfonilo, di(alquil)aminosulfonilalquilo, carboxilo, (hidroxi alquil)carbonilo, (hidroxialcoxi)carbonilo, alquilo inferior tri-halo sustituido y alcoxi inferior tri(halo) sustituido; A es seleccionado de entre el grupo consistente en -N(R4)(CH2)x-, -O(CH2)x-, -S(CH2)x-, -SO2(CH2)x-, -SO2N(CH2)x-, -NSO2(CH2)x-, -N(R4)(CH2)1-4O(CH2)x-, -N(R4)(CH2)1-4NH(CH2)x-, y N(R4)CNNH(CH2)x-, siendo x un número entero de 0 a 4; R4 es seleccionado de entre el grupo consistente en H, alquilo inferior, alquilo, hidroxialquilo, alcoxialquilo, arilalquilo, alquenilo inferior, alquenilo, arilo y heteroarilo; siendo arilo y heteroarilo opcionalmente sustituidos con 1 a 5 sustituyentes entre sí seleccionados de entre el grupo consistente en OH, halógeno, ciano, nitro, amino, alquilamino, di(alquil)amino, (hidroxialquil) amino, di(hidroxialquil)amino, alquilo, alquilo inferior, alcoxi, alcoxi inferior, alquilo inferior tri(halo) sustituido y alcoxi inferior tri(halo) sustituido; R2 es seleccionado de entre el grupo consistente en heteroarilo y biheteroarilo opcionalmente sustituido con de 1 a 2 sustituyentes independientemente entre sí R7 y un sustituyente seleccionado entre R8; R7 es seleccionado de entre el grupo consistente en alquilo, alquilo inferior, alcoxi inferior, alquenilo, alquinilo, heterociclilo, heterociclilalquilo, heterociclilalcoxi, arilo, arilalquilo, arilalcoxi, OH, hidroxialquilo, halógeno, ciano, nitro, amino, alquilamino, di(alquilo) amino, (hidroxialquil)amino, di(hidroxialquil) amino, carbamoílo, acilo, acilalquilo, alcoxicarbonilo, alcoxicarbonilalquilo, acilamino, alquilsulfonilo, alquilsulfonilamino, arilsulfonilamino (en el cual arilo está sustituido con de 1 a 3 sustituyentes seleccionados independientemente entre sí de entre el grupo consiste en ciano, halógeno, hidroxi, nitro, alquilo inferior tri (halo) sustituido y alcoxi inferior tri(halo)sustituido, carboxilo, (hidroxialquil) carbonilo, (hidroxialcoxi)carbonilo, alquilo inferior tri(halo) sustituido y alcoxi inferior tri(halo) sustituido; R8 es seleccionado de entre el grupo consistente en alquilo, OH, hidroxi alquilo, halógeno, ciano, amino, alquil amino, di(alquil) amino, (hidroxialquil) amino, di(hidroxialquil) amino, carbamoílo, alquilcarbonilamino, alquilcarbonilo, alcoxi carbonilo, (hidroxialquil)carbonilo, (hidroxialcoxi)carbonilo, O(CH2)nR5, O(CH2)nO(CH2)R5, O(CH2)nCH[(CH2)mR5]2, O(CH2)nN[(CH2)mR5]2, OCON[(CH2)]mR5]2, NH(CH2)nR5, NH(CH2)nCH(R5)2, NH(CH2)nSO2(CH2)mR5, NH(CH2)nO(CH2)mR5, NH(CH2)nOCH[(CH2)mR5]2, NH(CH2)nO(CH2)mO(CH2)mR5, NH(CH2)nN[(CH2)mR5]2, NH(CH2)nSO2NH(CH2)mR5, NH(CH2)nCH(OH) (CH2)mR5, NH(CH2)nCH(OH) (CH2)mOR5, NH(CH2)nCH(OH) (CH2)mN[(CH2)mR5]2, NH(CH2)nCO(CH2)mN[(CH2)mR5]2, NH(CH2)nCO2(CH2)mR5, NH(CH2)nCO(CH2)mSO2NH(CH2)mR5, NHCO(CH2)nCH(R5)2, NHCO(CH2)nR5, NHCO(CH2)nO(CH2)mR5, NHCO(CH2)nO(CH2)mO(CH2)mR5, NHCO(CH2)nO(CH2)mCO(CH2)mR5, NHCO(CH2)nN[(CH2)mR5]2, CONH(CH2)nO(CH2)mR5 y CONH(CH2)nN[(CH2)mR5]2; en lo cual n es un número entero de 0 a 6 y m es un número entero de 0 a 4; con la condición de que m es por lo menos 1 cuando R5 es seleccionado de entre el grupo consistente en OH, amino, alquilamino y di(alquil) amino. R5 es seleccionado de entre el grupo consiste en H, OH, alquilo inferior, amino, alquilamino, di(alquil) amino, arilo, heteroarilo, biheteroarilo y heterociclilo; siendo arilo, heteroarilo y heterociclilo opcionalmente sustituidos con de 1 a 3 sustituyentes independientemente entre sí seleccionados de entre el grupo consistente en alquilo, alquilo inferior, acilo, carboxilo, arilo (opcionalmente sustituido con de 1 a 5 sustituyentes halógeno), OH, halógeno, ciano, amino, alquil amino, di(alquil) amino, hidroxi (alquil) amino, di(hidroxialquil) amino, alquilsulfonilo, amino sulfonilo, alquilaminosulfonilo y aminosulfonilalquilo; y, en el cual heterociclilo está además opcionalmente sustituido con de 1 a 3 sustituyentes oxo; y R3 es seleccionado de entre el grupo consistente en H, alquilo, alquilo inferior, alcoxi, alcoxi inferior, alquenilo, alquinilo, heterociclilo, heterociclilalquilo, heterocicloalcoxi, arilo, arilalquilo, arilalcoxi, OH, hidroxi alquilo, halógeno, ciano, nitro, amino, alquil amino, di(alquil) amino, (hidroxialquil) amino, carbamoílo, acilo, acilalquilo, alcoxi carbonilo, alcoxicarbonilalquilo, acilamino, alquilsulfonilo, alquilsulfinil amino, arilsulfinil amino (siendo arilo sustituido con de 1 a 3 sustituyentes seleccionados independientemente entre sí de entre el grupo consistente en ciano, halógeno, hidroxi, nitro, alquilo inferior tri(halo) sustituido y alcoxi inferior tri (halo) sustituido, carboxilo, (hidroxi alquil) carbonilo, (hidroxi alcoxi) carbonilo, alquilo inferior tri(halo) sustituido y alcoxi inferior tri(halo) sustituido. Estos derivados de pirazina son particularmente útiles como inhibidores contra el dominio quinasa (enzima tirosn-quinasa)del Receptor del Factor de Crecimiento Endotelial Vascular (VEGF-R), que inhibe la actividad del receptor VEGF in vitro e in vivo. Estos compuestos son útiles para tratar enfermedades mediadas por la actividad del VEGF-R que incluyen, pero no se limitan a, cánceres de tumor sólido, angiogénesis, retinopatía diabética, artritis reumatoide, endometriosis y psoriasis. Además, se dan a conocer composiciones farmacéuticas que los comprenden, y los usos de tales compuestos y composiciones en la elaboración de medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23396800P | 2000-09-20 | 2000-09-20 | |
US09/955,780 US6710048B2 (en) | 2000-09-20 | 2001-09-19 | Pyrazine derivatives as modulators of tyrosine kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035494A1 true AR035494A1 (es) | 2004-06-02 |
Family
ID=22879359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010104452A AR035494A1 (es) | 2000-09-20 | 2001-09-20 | Derivados de pirazina, composiciones farmaceuticas que los comprenden, y los usos de tales compuestos y composiciones en la elaboracion de medicamento |
Country Status (14)
Country | Link |
---|---|
US (1) | US6710048B2 (es) |
EP (1) | EP1330452B1 (es) |
JP (1) | JP2004523474A (es) |
AR (1) | AR035494A1 (es) |
AT (1) | ATE415396T1 (es) |
AU (1) | AU9458401A (es) |
CA (1) | CA2423050A1 (es) |
DE (1) | DE60136731D1 (es) |
DK (1) | DK1330452T3 (es) |
ES (1) | ES2315308T3 (es) |
HK (1) | HK1054393B (es) |
PT (1) | PT1330452E (es) |
TW (1) | TWI254711B (es) |
WO (1) | WO2002024681A2 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
ES2310622T3 (es) * | 2001-12-19 | 2009-01-16 | Bristol-Myers Squibb Company | Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas. |
US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
AUPS251502A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Protein kinase inhibitors |
AUPS251402A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Kinase inhibitors |
WO2004000318A2 (en) * | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
GB0215775D0 (en) * | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
ES2378987T3 (es) * | 2002-08-06 | 2012-04-19 | Toray Industries, Inc. | Remedio o agente preventivo para una enfermedad renal y procedimiento para diagnosticar una enfermedad renal |
US8030336B2 (en) * | 2002-12-13 | 2011-10-04 | Ym Biosciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
US20040121968A1 (en) * | 2002-12-23 | 2004-06-24 | Alexander Ljubimov | Antiangiogenesis by inhibiting protein kinase CK2 activity |
OA13151A (en) * | 2003-02-26 | 2006-12-13 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors. |
GB2400101A (en) * | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
WO2005003101A2 (en) * | 2003-07-02 | 2005-01-13 | Biofocus Discovery Limited | Pyrazine and pyridine derivatives as rho kinase inhibitors |
EP1670794A2 (en) | 2003-09-30 | 2006-06-21 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
RU2377241C2 (ru) * | 2003-11-24 | 2009-12-27 | Ф.Хоффманн-Ля Рош Аг | Производные пиразоло-имидазопиримидина, обладающие антагонистической активностью в отношении кортикотропин-рилизинг фактора (crf) |
US20080194574A1 (en) * | 2003-12-16 | 2008-08-14 | Axxima Pharmaceuticals Ag | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases |
DE602005023587D1 (de) | 2004-01-21 | 2010-10-28 | Univ Emory | Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen |
EP1814856A1 (en) * | 2004-11-12 | 2007-08-08 | Galapagos N.V. | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
GB0500226D0 (en) * | 2005-01-07 | 2005-02-16 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
KR100674813B1 (ko) * | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
EP1917244A2 (de) | 2005-08-24 | 2008-05-07 | Abbott GmbH & Co. KG | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
US8466154B2 (en) | 2006-10-27 | 2013-06-18 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to wrapping of dehydrons |
TW200901880A (en) * | 2007-05-16 | 2009-01-16 | Bayer Cropscience Sa | Fungicide phenyl-pyrimidinyl-amino derivatives |
US8415358B2 (en) * | 2007-09-17 | 2013-04-09 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
KR100898037B1 (ko) * | 2007-10-05 | 2009-06-01 | 한국화학연구원 | 금속촉매의 커플링반응에 의한 트리알킬피라진 유도체의제조방법 |
US8716317B2 (en) | 2008-06-09 | 2014-05-06 | Sanofi | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
US20110112121A1 (en) * | 2009-07-06 | 2011-05-12 | Joerg Berghausen | Pharmaceutical Compositions and Solid Forms |
US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
CN108752280A (zh) | 2009-08-17 | 2018-11-06 | 纪念斯隆-凯特琳癌症中心 | 热休克蛋白结合化合物、组合物以及其制备和使用方法 |
CN102482265A (zh) * | 2009-09-04 | 2012-05-30 | 诺瓦提斯公司 | 用于治疗增殖性疾病的吡嗪基吡啶化合物 |
US20110185353A1 (en) * | 2010-01-27 | 2011-07-28 | Jack Matthew | Mitigating Problems Arising From Incompatible Software |
CA2816679A1 (en) * | 2010-11-17 | 2012-05-24 | Novartis Ag | 3-(aminoaryl)-pyridine compounds |
CN103339110A (zh) * | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
US9199962B2 (en) * | 2011-07-07 | 2015-12-01 | Merck Patent Gmbh | Substituted azaheterocycles for the treatment of cancer |
SG10201600149VA (en) | 2012-11-21 | 2016-02-26 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
EP3039015B1 (en) | 2013-08-30 | 2019-10-30 | PTC Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
WO2015076800A1 (en) * | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
US9878987B2 (en) | 2014-05-13 | 2018-01-30 | Memorial Sloan Kettering Cancer Center | HSP70 modulators and methods for making and using the same |
CA3058182A1 (en) | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
GB201715318D0 (en) | 2017-09-22 | 2017-11-08 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
GB201715414D0 (en) * | 2017-09-22 | 2017-11-08 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
TW202035375A (zh) | 2018-09-25 | 2020-10-01 | 美商卡都瑞恩醫藥有限責任公司 | 胺基嘧啶化合物 |
CA3184990A1 (en) | 2020-07-15 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
WO2022067082A1 (en) | 2020-09-28 | 2022-03-31 | Cardurion Pharmaceuticals, Llc | Fused heteroaryl compounds and their use as camkii inhibitors |
AU2022351219A1 (en) | 2021-09-21 | 2024-05-02 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
WO2023135107A1 (en) | 2022-01-11 | 2023-07-20 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4514400A (en) * | 1981-10-26 | 1985-04-30 | William H. Rorer, Inc. | Cardiotonic 5-heteroaryl-pyridone |
DE4426346A1 (de) * | 1994-07-25 | 1996-02-01 | Basf Ag | Herbizide Pyrazinderivate |
GB9514160D0 (en) * | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
JP2002511090A (ja) | 1997-06-30 | 2002-04-09 | アール・ジェイ・レイノルズ・タバコ・カンパニー | Cns疾患の予防と治療用3−ピリジル−1−アザ−ビシクロ−アルカン誘導体 |
CA2336254A1 (en) * | 1998-06-30 | 2000-01-06 | Daniel James Koch | 5-ht1f agonists |
IL148291A0 (en) * | 1999-09-16 | 2002-09-12 | Tanabe Seiyaku Co | Aromatic nitrogen-containing 6-membered cyclic compounds |
US6995161B2 (en) | 2000-02-16 | 2006-02-07 | Neurogen Corporation | Substituted arylpyrazines |
-
2001
- 2001-09-19 DE DE60136731T patent/DE60136731D1/de not_active Expired - Lifetime
- 2001-09-19 AT AT01975243T patent/ATE415396T1/de not_active IP Right Cessation
- 2001-09-19 US US09/955,780 patent/US6710048B2/en not_active Expired - Lifetime
- 2001-09-19 CA CA002423050A patent/CA2423050A1/en not_active Abandoned
- 2001-09-19 JP JP2002529091A patent/JP2004523474A/ja active Pending
- 2001-09-19 EP EP01975243A patent/EP1330452B1/en not_active Revoked
- 2001-09-19 DK DK01975243T patent/DK1330452T3/da active
- 2001-09-19 AU AU9458401A patent/AU9458401A/xx active Pending
- 2001-09-19 PT PT01975243T patent/PT1330452E/pt unknown
- 2001-09-19 WO PCT/US2001/029175 patent/WO2002024681A2/en active Application Filing
- 2001-09-19 ES ES01975243T patent/ES2315308T3/es not_active Expired - Lifetime
- 2001-09-20 AR ARP010104452A patent/AR035494A1/es not_active Application Discontinuation
-
2002
- 2002-09-05 TW TW091120227A patent/TWI254711B/zh not_active IP Right Cessation
-
2003
- 2003-09-19 HK HK03106746.1A patent/HK1054393B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60136731D1 (de) | 2009-01-08 |
TWI254711B (en) | 2006-05-11 |
ATE415396T1 (de) | 2008-12-15 |
HK1054393A1 (es) | 2003-11-28 |
WO2002024681A2 (en) | 2002-03-28 |
CA2423050A1 (en) | 2002-03-28 |
US20030060629A1 (en) | 2003-03-27 |
JP2004523474A (ja) | 2004-08-05 |
PT1330452E (pt) | 2009-01-22 |
HK1054393B (zh) | 2009-08-28 |
AU9458401A (en) | 2002-04-02 |
ES2315308T3 (es) | 2009-04-01 |
WO2002024681A3 (en) | 2002-06-20 |
US6710048B2 (en) | 2004-03-23 |
DK1330452T3 (da) | 2009-03-16 |
EP1330452B1 (en) | 2008-11-26 |
EP1330452A2 (en) | 2003-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035494A1 (es) | Derivados de pirazina, composiciones farmaceuticas que los comprenden, y los usos de tales compuestos y composiciones en la elaboracion de medicamento | |
US11945815B2 (en) | PTPN11 inhibitors | |
CN105899491B (zh) | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 | |
KR101593242B1 (ko) | 6-, 7- 또는 8-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법 | |
JP6215253B2 (ja) | 5−置換イソインドリン化合物 | |
JP6377068B2 (ja) | ピラゾロピリミジン化合物 | |
ES2293354T3 (es) | Derivados de pteridina sustituidos por heterociclos y su uso en terapia. | |
AR033525A1 (es) | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento | |
AR058403A1 (es) | PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF. | |
AR051738A1 (es) | Derivados de piridazin-3(2h)-ona, composicin farmaceutica, y uso del compuesto para fabricar medicamentos | |
AR050208A1 (es) | Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
CN101622015A (zh) | 药物组合物 | |
TW200521119A (en) | Compositions useful as inhibitors of voltage-gated ion channels | |
UY28940A1 (es) | Derivados de quinazolina | |
ZA200204557B (en) | Carbamate derivatives having muscarinic receptor antagonist activity. | |
CA2308994A1 (en) | Neuroprotective compounds | |
UY28522A1 (es) | Derivados de quinazolina | |
ES2963111T3 (es) | Derivados de 4-(1,3,4-oxadiazol-2-il)piridina-2(1H)-ona como inhibidores de la histona desacetilasa 6 (HDAC6) para el tratamiento de infecciones E.G | |
RU2008114048A (ru) | Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость | |
CN112135610A (zh) | 用于治疗癌症的选择性组蛋白去乙酰酶3(hdac3)抑制剂及免疫治疗剂的组合 | |
CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
RU2008127260A (ru) | Производные хиназолинона в качестве антагонистов ваниллоидов | |
PE20230251A1 (es) | Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
RU2009114731A (ru) | Производное пиразолопиримидина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal | ||
FB | Suspension of granting procedure |